QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% JV Reports IV Sapu003 Cuts GI Exposure to Everolimus by Up to 67-Fold
Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that…